COMPANY PROFILE // THE 014 REPORT
Soligenix, Inc.
SNGX (Nasdaq) · Formerly: DOR BIOPHARMA INC; ENDOREX CORP; IMMUNOTHERAPEUTICS INC
Assembled from 3 government sources in 2.7 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-06-12 and 2 more times (last 24 months).
- AmberLEI 549300MN2EF9LQHLT817 registration status is LAPSED (last update 2023-08-04): the legal-entity record has not been renewed.
✓ SEC filings✓ LEI✓ SAM registrationpossible match✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No IRS return, no state registration, no website, no lobbying registration on record.
SOLIGENIX, INC. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Princeton, NJ; listed as SNGX (Nasdaq).[source] It reported revenue of $119,371 for the fiscal year ended 2024-12-31.[source] It has filed 57 documents with the SEC in the last 12 months; the latest is Form 424B3, filed 2026-11-06.[source] Its largest institutional holders on 13F filings are CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, XTX Topco Ltd (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; LEI 549300MN2EF9LQHLT817 registration status is LAPSED (last update 2023-08-04).[source]
- red0
- amber2
- info0
- CITADEL ADVISORS LLC$83K
- JANE STREET GROUP, LLC$82K
- XTX Topco Ltd$62K
- GEODE CAPITAL MANAGEMENT, LLC$48K
- VANGUARD CAPITAL MANAGEMENT LLC$32K
- VANGUARD FIDUCIARY TRUST CO$21K
- NORTHERN TRUST CORP$15K
- JONES FINANCIAL COMPANIES LLLP$507
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Donini Oreola · CSO (Officer) · latest Form 4 2025-12-12 · filing · LinkedIn search
- Guarino Jonathan L. · CFO (Officer) · latest Form 4 2025-12-12 · filing · LinkedIn search
- SCHABER CHRISTOPHER J · CHAIRMAN, CEO AND PRESIDENT (Director,Officer) · latest Form 4 2025-12-12 · filing · LinkedIn search
- Straube Richard · CMO (Consulting) (Officer) · latest Form 4 2025-12-12 · filing · LinkedIn search
- LAPOINTE ANTHONY GREGG · Director · latest Form 4 2025-06-20 · filing · LinkedIn search
- Parks Diane L. · Director · latest Form 4 2025-06-20 · filing · LinkedIn search
- RUBIN ROBERT J. · Director · latest Form 4 2025-06-20 · filing · LinkedIn search
- ZELDIS JEROME B · Director · latest Form 4 2025-06-20 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Duane Morris LLP · Exhibit 5.1 legal opinion, S-8 filed 2025-06-20
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000812796 | source |
| LEI | 549300MN2EF9LQHLT817 | source |
| UEIpossible match | GVD4XBVYD9J5 | source |
| CAGEpossible match | 44FA7 | source |
| EIN | 41-1505029 | source |
| Business address (SEC) | 29 EMMONS DRIVE, PRINCETON, NJ, 08540 | source |
Does not exist in the records we hold: NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2017-11-10 · in -3,297 days · LEI next renewal (549300MN2EF9LQHLT817)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-07-14 · in 236 days · SAM registration expires (UEI GVD4XBVYD9J5)possible match
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
Federal contractors nearby in the same code (6)
- HELLO BIO INC · SAM Active
- TARGERON THERAPEUTICS LLC · SAM Active
- SOLIGENIX, INC. · SAM Active
- LUNGEVIA BIO INC · SAM Active
- RICOVR HEALTHCARE INC · SAM Active
- ANTIGENIX THERAPEUTICS INC · SAM Active
registered in SAM.gov with the same ZIP code (08540) and the same primary NAICS code (541714), extract 2026-11-01
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- RIGEL PHARMACEUTICALS INC · LAPOINTE ANTHONY GREGG
- Kura Oncology, Inc. · Parks Diane L.
- Celularity Inc · Parks Diane L.
- PTC THERAPEUTICS, INC. · ZELDIS JEROME B
- NEXGEL, INC. · ZELDIS JEROME B
EVERY SOURCE · NEWEST FIRST
One timeline
- 2027-07-14 registration SAM registration expiry (UEI GVD4XBVYD9J5) · SAM.gov
- 2026-11-06 filing 424B3 · SEC EDGAR
- 2026-11-06 filing 424B3 · SEC EDGAR
- 2026-11-06 filing 424B3 · SEC EDGAR
- 2026-11-06 filing 424B3 · SEC EDGAR
- 2026-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-06 name change Name changed from SOLIGENIX, INC. · SEC EDGAR
- 2026-09-21 filing 8-K items 5.03,5.07,8.01,9.01 · SEC EDGAR
- 2026-08-07 filing 424B3 · SEC EDGAR
- 2026-08-07 filing 424B3 · SEC EDGAR
- 2026-08-07 filing 424B3 · SEC EDGAR
- 2026-08-07 filing 424B3 · SEC EDGAR
- 2026-08-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-03 filing ARS · SEC EDGAR
- 2026-08-03 filing DEFA14A · SEC EDGAR
- 2026-08-03 filing Proxy statement · SEC EDGAR
- 2026-07-23 filing PRER14A · SEC EDGAR
- 2026-07-21 filing PRE 14A · SEC EDGAR
- 2026-06-26 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-26 filing 424B5 · SEC EDGAR
- 2026-06-12 officer change 8-K items 3.01,5.02,8.01,9.01 · SEC EDGAR
- 2026-05-28 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-28 filing 424B5 · SEC EDGAR
- 2026-05-08 filing 424B3 · SEC EDGAR
- 2026-05-08 filing 424B3 · SEC EDGAR
- 2026-05-08 filing 424B3 · SEC EDGAR
- 2026-05-08 filing 424B3 · SEC EDGAR
- 2026-05-08 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-28 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-04-02 filing EFFECT · SEC EDGAR
170 earlier entries
- 2026-04-02 filing EFFECT
- 2026-04-02 filing EFFECT
- 2026-04-02 filing EFFECT
- 2026-03-31 filing POS AM
- 2026-03-31 filing POS AM
- 2026-03-31 filing POS AM
- 2026-03-31 filing POS AM
- 2026-03-31 filing Annual report (10-K)
- 2026-02-12 filing 8-K items 8.01,9.01
- 2026-01-23 filing 424B5
- 2026-01-23 filing 8-K items 8.01,9.01
- 2025-12-12 insider First Form 3/4/5 on record for Donini Oreola (CSO)
- 2025-12-12 insider First Form 3/4/5 on record for Guarino Jonathan L. (CFO)
- 2025-12-12 insider First Form 3/4/5 on record for Straube Richard (CMO (Consulting))
- 2025-11-18 filing 8-K items 3.01,9.01
- 2025-11-07 filing 424B3
- 2025-11-07 filing 424B3
- 2025-11-07 filing 424B3
- 2025-11-07 filing Quarterly report (10-Q)
- 2025-10-03 insider First Form 3/4/5 on record for SCHABER CHRISTOPHER J (CHAIRMAN, CEO AND PRESIDENT)
- 2025-09-29 filing 8-K items 1.01,8.01,9.01
- 2025-09-26 filing 424B4
- 2025-09-25 filing EFFECT
- 2025-09-23 filing CORRESP
- 2025-09-23 filing CORRESP
- 2025-09-19 filing Registration (S-1)
- 2025-09-02 filing UPLOAD
- 2025-08-27 filing DRS
- 2025-08-18 filing 8-K items 8.01,9.01
- 2025-08-15 filing 424B3
- 2025-08-15 filing 8-K items 3.01,9.01
- 2025-08-15 filing 424B3
- 2025-08-15 filing 424B3
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-07-31 filing 8-K items 8.01,9.01
- 2025-06-20 filing S-8
- 2025-06-20 officer change 8-K items 5.02,5.07,9.01
- 2025-06-20 insider First Form 3/4/5 on record for LAPOINTE ANTHONY GREGG (Director)
- 2025-06-20 insider First Form 3/4/5 on record for Parks Diane L. (Director)
- 2025-06-20 insider First Form 3/4/5 on record for RUBIN ROBERT J. (Director)
- 2025-06-20 insider First Form 3/4/5 on record for ZELDIS JEROME B (Director)
- 2025-05-09 filing Quarterly report (10-Q)
- 2025-05-05 filing ARS
- 2025-05-05 filing DEFA14A
- 2025-05-05 filing Proxy statement
- 2025-03-28 filing 8-K items 5.03,9.01
- 2025-03-26 filing EFFECT
- 2025-03-26 filing EFFECT
- 2025-03-26 filing EFFECT
- 2025-03-21 filing POS AM
- 2025-03-21 filing POS AM
- 2025-03-21 filing POS AM
- 2025-03-21 filing Annual report (10-K)
- 2025-02-10 filing 8-K items 1.02
- 2024-11-08 filing 424B3
- 2024-11-08 filing 424B3
- 2024-11-08 filing 424B3
- 2024-11-08 filing Quarterly report (10-Q)
- 2024-10-11 filing 8-K items 1.01,2.03,9.01
- 2024-08-16 filing 424B5
- 2024-08-16 filing 8-K items 8.01,9.01
- 2024-08-09 filing 424B3
- 2024-08-09 filing 424B3
- 2024-08-09 filing Quarterly report (10-Q)
- 2024-08-02 filing EFFECT
- 2024-07-30 filing CORRESP
- 2024-07-29 filing UPLOAD
- 2024-07-25 filing 8-K items 1.01
- 2024-07-24 filing Registration (S-1)
- 2024-07-09 filing 8-K items 1.01,3.02,9.01
- 2024-05-31 officer change 8-K items 3.03,5.02,5.03,5.07,7.01,9.01
- 2024-05-29 filing DEFA14A
- 2024-05-28 filing DEFA14A
- 2024-05-24 filing 8-K items 5.07,7.01,9.01
- 2024-05-22 filing DEFA14A
- 2024-05-17 filing 8-K items 8.01,9.01
- 2024-05-17 filing DEFA14A
- 2024-05-15 filing DEFA14A
- 2024-05-10 filing 424B3
- 2024-05-10 filing Quarterly report (10-Q)
- 2024-04-29 filing ARS
- 2024-04-29 filing Proxy statement
- 2024-04-22 filing 8-K items 1.01,8.01,9.01
- 2024-04-19 filing PRE 14A
- 2024-04-19 filing 424B4
- 2024-04-15 filing EFFECT
- 2024-04-15 filing CORRESP
- 2024-04-15 filing CORRESP
- 2024-04-03 filing CORRESP
- 2024-04-03 filing 8-K items 8.01,9.01
- 2024-04-02 filing CORRESP
- 2024-04-02 filing CORRESP
- 2024-04-02 filing S-1/A
- 2024-03-15 filing S-1/A
- 2024-03-15 filing Annual report (10-K)
- 2024-01-19 filing UPLOAD
- 2024-01-16 filing Registration (S-1)
- 2023-12-22 filing 8-K items 3.01,9.01
- 2023-12-15 filing EFFECT
- 2023-12-15 filing 8-K items 5.07,9.01
- 2023-12-14 filing CORRESP
- 2023-12-08 filing S-3/A
- 2023-12-06 filing CORRESP
- 2023-11-30 filing CORRESP
- 2023-11-17 filing 8-K items 5.07,7.01,9.01
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-10-20 filing 8-K items 5.07,7.01,9.01
- 2023-10-17 filing DEFA14A
- 2023-10-17 filing DEFA14A
- 2023-10-16 filing DEFA14A
- 2023-10-13 filing DEFA14A
- 2023-10-12 filing DEFA14A
- 2023-10-12 filing DEFA14A
- 2023-09-22 filing DEFA14A
- 2023-09-22 filing 8-K items 5.07,7.01,9.01
- 2023-09-15 filing DEFA14A
- 2023-09-15 filing 8-K items 4.01,8.01,9.01
- 2023-09-12 filing UPLOAD
- 2023-08-30 filing S-3
- 2023-08-21 filing Quarterly report (10-Q)
- 2023-08-14 filing NT 10-Q
- 2023-08-07 filing ARS
- 2023-08-07 filing DEFA14A
- 2023-08-07 filing Proxy statement
- 2023-07-07 officer change 8-K items 5.02
- 2023-06-23 filing 8-K items 3.01
- 2023-05-26 filing 8-K items 3.01
- 2023-05-15 filing Quarterly report (10-Q)
- 2023-05-09 filing 8-K items 1.01,8.01,9.01
- 2023-05-08 filing 424B4
- 2023-05-05 filing EFFECT
- 2023-05-04 filing CORRESP
- 2023-05-04 filing S-1/A
- 2023-05-03 officer change 8-K items 1.01,5.02,9.01
- 2023-05-01 filing 8-K items 8.01,9.01
- 2023-04-20 filing S-1/A
- 2023-04-19 filing CORRESP
- 2023-04-19 filing 8-K items 1.01,2.03,9.01
- 2023-04-14 filing 8-K items 8.01,9.01
- 2023-04-10 filing 8-K items 3.01
- 2023-04-07 filing UPLOAD
- 2023-03-31 filing Registration (S-1)
- 2023-03-31 filing Annual report (10-K)
- 2023-02-24 filing 8-K items 3.01
- 2023-02-14 filing 8-K items 8.01,9.01
- 2023-02-09 officer change 8-K items 3.03,5.02,5.03,5.07,7.01,9.01
- 2023-01-11 filing DEFA14A
- 2023-01-11 filing 8-K items 8.01
- 2023-01-06 filing Proxy statement
- 2022-12-27 filing 8-K items 3.03,5.03,7.01,9.01
- 2022-12-27 filing 8-A12G
- 2022-12-23 filing PRE 14A
- 2022-12-23 filing 8-K items 3.01
- 2022-12-19 filing 8-K items 8.01,9.01
- 2022-12-15 filing 8-K items 8.01,9.01
- 2022-11-18 filing 8-K items 3.01,5.07,9.01
- 2022-11-16 filing DEFA14A
- 2022-11-15 filing DEFA14A
- 2022-11-14 filing DEFA14A
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-11-09 filing DEFA14A
- 2022-10-28 filing S-8
- 2022-10-27 filing 8-K items 7.01,9.01
- 2022-10-25 filing 8-K items 7.01,9.01
- 2022-10-20 filing 8-K items 5.07,7.01,9.01
- 2022-10-05 filing DEFA14A
- 2022-09-23 officer change 8-K items 5.02,5.07,7.01,9.01
- 2022-09-13 filing DEFA14A
- 2022-08-12 filing Quarterly report (10-Q)
- 2022-08-09 filing DEFA14A
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-06 (within 30 days) 424B3 filed
- 2026-11-06 (within 30 days) 424B3 filed
- 2026-11-06 (within 30 days) 424B3 filed
- 2026-11-06 (within 30 days) 424B3 filed
- 2026-11-06 (within 30 days) 10-Q filed
- 2026-09-21 (older) 8-K filed: Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-07 (older) 424B3 filed
- 2026-08-07 (older) 424B3 filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SNGX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above; 2 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 812796 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SNGX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300MN2EF9LQHLT817 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300MN2EF9LQHLT817) | GLEIF |
| EIN | 411505029 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000812796 | SEC EDGAR / IRS |
| CUSIP | 834223604 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000812796 | SEC EDGAR |
former name (shown apart, not merged) (2)
- former nameENDOREX CORP · EPA ECHO facilities
- former nameIMMUNOTHERAPEUTICS INC. · EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2024-12-31) | $119,371 | 2024-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-20 10:22 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$11,080,380 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:22 UTC | Report an error |
| Total assets (at 2025-12-31) | $9,235,521 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:22 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $5,292,125 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:22 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $7,936,153 | 2025-12-31 | 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | as filed | 2026-11-20 10:22 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-06 | SEC EDGAR company profile | as filed | 2026-11-20 10:22 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-06 | SEC EDGAR company profile | as filed | 2026-11-20 10:22 UTC | Report an error |
| State of incorporation | DE | 2026-11-06 | SEC EDGAR company profile | as filed | 2026-11-20 10:22 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-06 | SEC EDGAR company profile | as filed | 2026-11-20 10:22 UTC | Report an error |
| Business address | 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540 | 2026-11-06 | SEC EDGAR company profile | as filed | 2026-11-20 10:22 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-06 | SEC EDGAR company profile | as filed | 2026-11-20 10:22 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$10,266,553 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:22 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $5,883 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:22 UTC | Report an error |
| Long-term debt (at 2024-12-31) | $0 | 2024-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-20 10:22 UTC | Report an error |
| Form D total offering amount (D filed 2017-11-08) | $1,964,000 | 2017-11-08 | D | as filed | 2026-11-20 10:22 UTC | Report an error |
| Form D total amount sold (D filed 2017-11-08) | $1,964,000 | 2017-11-08 | D | as filed | 2026-11-20 10:22 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2017-11-08 | D | as filed | 2026-11-20 10:22 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2017-11-08 | D | as filed | 2026-11-20 10:22 UTC | Report an error |
| Form D date of first sale | 2017-11-02 | 2017-11-08 | D | as filed | 2026-11-20 10:22 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-06 · accession 0001104659-26-123855
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$1,117,525 | 3 months ended 2026-09-30 | 10-Q | 2026-11-06 | 0001104659-26-123855 | 2026-11-20 10:22 UTC | Report an error |
| Cash and cash equivalents | $9,023,510 | at 2026-09-30 | 10-Q | 2026-11-06 | 0001104659-26-123855 | 2026-11-20 10:22 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-06 Filing 424B3 filed
- 2026-11-06 Filing 424B3 filed
- 2026-11-06 Filing 424B3 filed
- 2026-11-06 Filing 424B3 filed
- 2026-11-06 Filing 10-Q filed
- 2026-09-21 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-07 Filing 424B3 filed
- 2026-08-07 Filing 424B3 filed
- 2026-08-07 Filing 424B3 filed
- 2026-08-07 Filing 424B3 filed
- 2026-08-07 Filing 10-Q filed
- 2026-08-03 Filing ARS filed
- 2026-08-03 Filing DEFA14A filed
- 2026-08-03 Filing DEF 14A filed (FORM DEF 14A)
- 2026-07-23 Filing PRER14A filed (FORM- PRER14A)
- 2026-07-21 Filing PRE 14A filed
- 2026-06-26 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-26 Filing 424B5 filed
- 2026-06-12 Filing 8-K filed: Item 3.01 delisting notice; Item 5.02 officer or director change; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-28 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-28 Filing 424B5 filed
- 2026-05-08 Filing 424B3 filed
- 2026-05-08 Filing 424B3 filed
- 2026-05-08 Filing 424B3 filed
- 2026-05-08 Filing 424B3 filed
8-K item text, as filed (excerpts)
- 2026-09-21 8-K Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. To the extent required by Item 5.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. As described below in Item 5.07, on September 17, 2026, Soligenix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”), at which the stockholders approved and adopted an amendment to the Second Amended and Restated Certificate of Incorporation (“Charter Amendment”), which increased the number of authorized shares of Common Stock from 75,000,000 to 125,000,000. The Charter Amendment became effective upon filing with the… the 8-K · retrieved 2026-11-20 10:22 UTC - 2026-09-21 8-K Item 5.07, Submission of Matters to a Vote of Security Holders
On September 17, 2026, at the Annual Meeting, the following seven items were voted upon: Proposal 1 – Election of Directors: The following five nominees were elected as directors to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, by votes as follows: Name For Withheld Christopher J. Schaber, PhD 2,819,961 319,789 Gregg A. Lapointe, CPA, MBA 2,844,872 294,878 Diane L. Parks, MBA 2,844,499 295,251 Robert J. Rubin, MD 2,846,498 293,252 Jerome B. Zeldis, MD, PhD 2,845,304 294,446 There were 7,470,895 broker non-votes in the election of directors. Proposal 2 – Reverse Stock Split Proposal: The proposal to approve an… the 8-K · retrieved 2026-11-20 10:22 UTC - 2026-09-21 8-K Item 8.01, Other Events
On June 26, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC, by an additional aggregate amount of $2,500,000. The Company previously sold approximately $6,234,000 of shares of common stock pursuant to the Sales Agreement under prior prospectus supplements covering an aggregate of up to $6,406,000 of shares of common stock. A copy of the legal opinion as to the legality of the $2,500,000… the 8-K · retrieved 2026-11-20 10:22 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $82,965 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 2 | JANE STREET GROUP, LLC | $82,166 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 3 | XTX Topco Ltd | $62,219 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | $47,624 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $32,078 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 6 | VANGUARD FIDUCIARY TRUST CO | $21,350 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 7 | NORTHERN TRUST CORP | $15,066 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 8 | JONES FINANCIAL COMPANIES LLLP | $507 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 9 | JPMORGAN CHASE & CO | $98 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
| 10 | Plante Moran Financial Advisors, LLC | $83 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:22 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- Soligenix, Inc. · LEI 549300MN2EF9LQHLT817 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSOLIGENIX, INC. · exact legal name · sx:usaspending:GVD4XBVYD9J5 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/812796.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000812796. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.